Epitor Therapeutics is advancing the next generation of epigenetic editors to treat diseases with high unmet need.

Megan has over 10 years of experience across healthcare including clinical medicine, research, management consulting, and drug development. She received a BA, magna cum laude, from the University of Pennsylvania in neuroscience, chemistry and music. She completed her MD and PhD degrees at New York University with a PhD in neuroimaging and MRI physics and was elected to Alpha Omega Alpha Honor Medical Society. Megan trained as a radiologist at NYU Langone Medical Center and previously held roles at McKinsey & Co. in the firm's healthcare practice, Regenxbio, a gene therapy company, and BridgeBio, a genetic disease company. Megan is currently the CEO of Epitor Therapeutics (epigenetic editing) and HitchBio (red blood cell drug delivery).